

STN Search

FILE 'HOME' ENTERED AT 16:52:06 ON 02 JUL 2007

=> FILE BIOSCI

=> S (measur?(A)(triglycerid?)) AND (poloxyalkylene OR polyoxyethylene? OR POE)

23 FILES SEARCHED...

45 FILES SEARCHED...

L1 51 (MEASUR?(A)(TRIGLYCERID?)) AND (POLOXYALKYLENE OR POLYOXYETHYLEN
E? OR POE)

=> DUP REM L1

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR,
PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L1

L2 42 DUP REM L1 (9 DUPLICATES REMOVED)

=> display abs bib L2

ENTER ANSWER NUMBER OR RANGE (1):1-10

L2 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

AB Provided is a convenient and accurate method/kit for measuring
triglyceride in low-d. lipoprotein in a test sample, which is
characterized by sequentially carrying out: (i) a step for generating free
glycerol by allowing lipoprotein lipase to react with on the test sample
in an aqueous medium containing the test sample and a specific surfactant such
as

polyoxyethylene polyoxyalkylene polycyclic Ph ether; (ii) a step
for removing free glycerol present in the reaction solution in the step (i);
(iii) a step for generating free glycerol by allowing lipoprotein lipase
to react with the reaction solution after removing free glycerol in the step
(ii) in the presence of a specific surfactant such as
polyoxyethylene polyoxyalkylene alkyl ether; and (iv) a step for
measuring free glycerol generated in the step (iii).

AN 2007:509730 CAPLUS

DN 146:458024

TI Method and kit for measuring triglyceride in
low-density lipoprotein

IN Katayama, Yuki; Miyauchi, Kazuhito; Takada, Shizuyo; Uchida, Tomomi

PA Kyowa Medex Co., Ltd., Japan

SO PCT Int. Appl., 64pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007052646	A1	20070510	WO 2006-JP321730	20061031
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,				
	KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,				
	MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,				
	RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				
	GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2005-316476	A	20051031		
	JP 2006-95151	A	20060330		

OS MARPAT 146:458024

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 42 USPATFULL on STN

AB Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related; weight-related and/or cholesterol-related conditions in an animal subject.

AN 2007:155165 USPATFULL

TI Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors

IN Chang, Han-Ting, Livermore, CA, UNITED STATES
Charmot, Dominique, Campbell, CA, UNITED STATES
Glinka, Tomasz, Cupertino, CA, UNITED STATES
Cope, Michael James, Berkeley, CA, UNITED STATES
Goka, Elizabeth, San Jose, CA, UNITED STATES
Shao, Jun, Fremont, CA, UNITED STATES
Cartigny, Damien, Rouen, FRANCE
Chen, Shiah-yun, Mountain View, CA, UNITED STATES
Buysse, Jerry M., Los Altos, CA, UNITED STATES

PI US 2007135385 A1 20070614

AI US 2006-593177 A1 20061103 (11)

PRAI US 2005-733954P 20051103 (60)

DT Utility

FS APPLICATION

LREP ILYPSA-McANDREWS, C/O MCANDREWS, HELD & MADISON STREET, 500 WEST MADISON STREET, SUITE 3400, CHICAGO, IL, 60661, US

CLMN Number of Claims: 34

ECL Exemplary Claim: 1-104

DRWN 38 Drawing Page(s)

LN.CNT 7696

L2 ANSWER 3 OF 42 USPATFULL on STN

AB The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

AN 2007:155163 USPATFULL

TI Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors

IN Chang, Han-Ting, Livermore, CA, UNITED STATES
Charmot, Dominique, Campbell, CA, UNITED STATES
Glinka, Tomasz, Cupertino, CA, UNITED STATES
Cope, Michael James, Berkeley, CA, UNITED STATES
Goka, Elizabeth, San Jose, CA, UNITED STATES
Shao, Jun, Fremont, CA, UNITED STATES
Cartigny, Damien, Rouen, FRANCE
Chen, Shiah-yun, Mountain View, CA, UNITED STATES
Buysse, Jerry M., Los Altos, CA, UNITED STATES

PI US 2007135383 A1 20070614

AI US 2006-593176 A1 20061103 (11)

PRAI US 2005-734037P 20051103 (60)

DT Utility

FS APPLICATION

LREP ILYPSA-McANDREWS, C/O MCANDREWS, HELD & MADISON STREET, 500 WEST MADISON

STREET, SUITE 3400, CHICAGO, IL, 60661, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1-68
DRWN 47 Drawing Page(s)
LN.CNT 10023

L2 ANSWER 4 OF 42 USPATFULL on STN

AB This invention is directed to indole acetic acid derivatives and their use in pharmaceutical compositions for the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease. The invention is also directed to intermediates useful in preparation of indole acetic derivatives and to methods of preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:308873 USPATFULL
TI Indole acetic acid derivatives and their use as pharmaceutical agents
IN Ma, Xin, Bethany, CT, UNITED STATES
Cantin, Louis-David, Hamden, CT, UNITED STATES
Choi, Soongyu, Skillman, NJ, UNITED STATES
Clark, Roger, Middletown, CT, UNITED STATES
Hentemann, Martin, Hamden, CT, UNITED STATES
Rudolph, Joachim, Guilford, CT, UNITED STATES
Lavoie, Rico, Hamden, CT, UNITED STATES
Zhang, Zhonghua, Derby, CT, UNITED STATES
PI US 2006264486 A1 20061123
AI US 2004-555024 A1 20040428 (10)
WO 2004-US12959 20040428
20051026 PCT 371 date
PRAI US 2003-466143P 20030428 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 42 USPATEFULL on STN

AB A pharmaceutical composition comprising: (i) metformin, optionally in the form of one of its pharmaceutically acceptable salts, (ii) a statin, optionally in the form one of its pharmaceutically acceptable salts, and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of hyperglycemia non-insulin-dependent diabetes, dyslipidemia, hyperlipidemia, hypercholesterolemia, and obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:281155 USPATFULL
TI Pharmaceutical composition comprising a combination of metformin and a statin
IN Junien, Jean-Louis, Sevres, FRANCE
Edgar, Alan, Saint Julien, FRANCE
PI US 2006240095 A1 20061026
AI US 2004-568523 A1 20040820 (10)
WO 2004-EP9337 20040820
20060215 PCT 371 date
PRAI EP 2003-292077 20030822
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 42 USPATFULL on STN

AB This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:241274 USPATFULL

TI Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

IN Lowe, Derek B., Hamden, CT, UNITED STATES

Wickens, Philip L., Wallingford, CT, UNITED STATES

Ma, Xin, Bethany, CT, UNITED STATES

Zhang, Mingbao, Stamford, CT, UNITED STATES

Bullock, William H., Easton, CT, UNITED STATES

Coish, Philip D. G., New Haven, CT, UNITED STATES

Mugge, Ingo A., New Haven, CT, UNITED STATES

Stolle, Andreas, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

Wang, Ming, Milford, CT, UNITED STATES

Wang, Yamin, Sandy Hook, CT, UNITED STATES

Zhang, Chengzhi, Orange, CT, UNITED STATES

Zhang, Hai-Jun, Middletown, CT, UNITED STATES

Zhu, Lei, Milford, CT, UNITED STATES

Tsutsumi, Manami, Stratford, CT, UNITED STATES

Livingston, James N., Guilford, CT, UNITED STATES

PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)

PI US 2006205723 A1 20060914

AI US 2006-429136 A1 20060505 (11)

RLI Division of Ser. No. US 2004-949119, filed on 22 Sep 2004, PENDING

Continuation of Ser. No. US 2002-205839, filed on 25 Jul 2002, GRANTED, Pat. No. US 6828335

PRAI US 2001-308500P 20010727 (60)

US 2002-373048P 20020416 (60)

DT Utility

FS APPLICATION

LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516, US

CLMN Number of Claims: 140

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5281

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 42 USPATFULL on STN

AB The object of the present invention is to provide a fast and simple method for fractional measurement of a small particle LDL. A method for quantifying a small particle low density lipoprotein in a test sample, comprising a first step for separating the small particle low density lipoprotein from other low density lipoproteins, and a second step for measuring cholesterol, triglycerides or proteins in the separated small particle low density lipoprotein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:181976 USPATFULL

TI Method of quantifying small-sized low density lipoprotein

IN Itoh, Yasuki, Niigata, JAPAN

Hirano, Tsutomu, Tokyo, JAPAN

PI US 2006154374 A1 20060713

AI US 2003-537766 A1 20031205 (10)
WO 2003-JP15633 20031205
20050606 PCT 371 date

PRAI JP 2002-355119 20021206
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC,
20007, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 42 USPATFULL on STN
AB This invention relates to 1,5,6,7-tetrahydropynolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:144696 USPATFULL
TI Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity
IN Smith, Roger A., Madison, CT, UNITED STATES
O'Connor, Stephen J., Guilford, CT, UNITED STATES
Wong, Wai C., Hamden, CT, UNITED STATES
Choi, Soongyu, Trumbull, CT, UNITED STATES
Kluender, Harold C. E., Trumbull, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
Zhang, Zhonghua, Derby, CT, UNITED STATES
Lavoie, Rico C., Hamden, CT, UNITED STATES
Podlogar, Brent L., Hamden, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)
PI US 2006122215 A1 20060608
AI US 2006-335349 A1 20060118 (11)
RLI Division of Ser. No. US 2004-487976, filed on 27 Feb 2004, PENDING A 371 of International Ser. No. WO 2002-US30541, filed on 24 Sep 2002
PRAI US 2001-324443P 20010924 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516, US
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 42 USPATFULL on STN
AB This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:99507 USPATFULL
TI Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
IN Cantin, Louis-David, Hamden, CT, UNITED STATES

Choi, Soongyu, Skillman, NJ, UNITED STATES
Clark, Roger B, Middletown, CT, UNITED STATES
Hentemann, Martin F, Hamden, CT, UNITED STATES
Ma, Xin, Bethany, CT, UNITED STATES
Rudolph, Joachim, Guilford, CT, UNITED STATES
Liang, Sidney X, Bethany, CT, UNITED STATES
Akuche, Christiana, Hamden, CT, UNITED STATES
Lavoie, Rico C, Hamden, CT, UNITED STATES
Chen, Libing, Milford, CT, UNITED STATES
Majumdar, Dyuti, Milford, CT, UNITED STATES
Wickens, Philip L, Wallingford, CT, UNITED STATES

PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES, 06516
(U.S. corporation)

PI US 2006084680 A1 20060420

AI US 2003-537630 A1 20031219 (10)

WO 2003-US40842 20031219

20050603 PCT 371 date

PRAI US 2002-435310P 20021220 (60)

DT Utility

FS APPLICATION

LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516, US

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6496

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 42 USPATFULL on STN

AB The present invention relates to methods for assessing enzyme activity
utilizing a phase partition system. In addition, the present invention
also relates to methods for screening and identifying compounds that may
be used, for example, for the treatment of diabetes, diabetes-related
disorders, obesity, cardiovascular disease, cancer, and other diseases
or disorders, using this phase partition system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:80463 USPATFULL

TI Methods for screening and identifying compounds

IN Landro, James A., Cheshire, CT, UNITED STATES

Osterman, David G., Glastonbury, CT, UNITED STATES

Pickett, Walter, Madison, CT, UNITED STATES

PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S.
corporation)

PI US 2006068456 A1 20060330

AI US 2005-266030 A1 20051102 (11)

RLI Division of Ser. No. US 2004-911242, filed on 4 Aug 2004, GRANTED, Pat.
No. US 6994956

PRAI US 2003-492763P 20030804 (60)

DT Utility

FS APPLICATION

LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516, US

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 1535

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> DISPLAY L2

ENTER ANSWER NUMBER OR RANGE (1):11-25

ENTER DISPLAY FORMAT (FILEDEFAULT):abs bib

L2 ANSWER 11 OF 42 USPATFULL on STN

AB Drugs and foods for preventing and/or treating liver diseases, hyperlipemia and/or diabetes containing a peptide which is composed of L-amino acids constituting natural proteins, has an L-glutamine content of from 15 to 60% by mass and has an average molecular weight of from 200 to 100,000; and foods containing this peptide. By taking the above drugs or foods, effects of preventing or treating liver diseases, hyperlipemia and/or diabetes can be exhibited. These drugs and foods are highly efficacious and can be easily taken without any fear of side effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:60234 USPATFULL

TI Remedies for liver diseases, hyperlipemia and diabetes

IN Horiguchi, Noboru, Sakaide, JAPAN

Horiguchi, Hiroshi, Sakaide, JAPAN

Suzuki, Yoshio, Chiyoda-ku, JAPAN

PI US 2006051399 A1 20060309

AI US 2005-211688 A1 20050826 (11)

RLI Continuation of Ser. No. US 2004-506211, filed on 1 Sep 2004, ABANDONED

A 371 of International Ser. No. WO 2003-JP2366, filed on 28 Feb 2003

PRAI JP 2002-55812 20020301

JP 2002-278880 20020925

JP 2002-278881 20020925

DT Utility

FS APPLICATION

LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,

WASHINGTON, DC, 20006-1021, US

CLMN Number of Claims: 9

ECL Exemplary Claim: 1-6

DRWN No Drawings

LN.CNT 853

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 42 USPATFULL on STN

AB A procedure is described for the determination of triglyceride contained in low density lipoprotein with the measures that triglyceride-containing lipoprotein is reacted with a non-ionic surface-active agent which is synthesized from a block copolymer of propylene oxide and ethylene oxide, and that a triglyceride determination method is carried out. The procedure is particularly suitable for the in-vitro diagnosis of vascular disorders, in particular in the detection of coronary heart disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:23904 USPATFULL

TI Procedure for the determination of triglyceride contained in low density lipoprotein

IN Wieland, Heinrich, St. Peter, GERMANY, FEDERAL REPUBLIC OF

Nauck, Matthias, Freiburg i. Br., GERMANY, FEDERAL REPUBLIC OF

PA Roche Diagnostics GmbH, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US 6991913 B1 20060131

AI US 2000-597592 20000616 (9)

RLI Continuation of Ser. No. WO 1998-EP8253, filed on 16 Dec 1998, PENDING

PRAI DE 1997-19756255 19971217

DT Utility

FS GRANTED

EXNAM Primary Examiner: Kruse, David H.; Assistant Examiner: Hwu, June.

LREP McDonnell Boehnen Hulbert & Berghoff LLP

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 576

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 42 IFIPAT COPYRIGHT 2007 IFI on STN DUPLICATE 2

AB The present invention relates to a reagent for selective measurement of triglycerides contained in very low density lipoprotein and intermediate density lipoprotein or in very low density lipoprotein in a test sample, including a first reagent that contains a first selective reaction promoter, which is an ether or ester compound of a polyoxyalkylene capable of reacting lipoprotein lipase selectively with triglycerides contained in low density lipoprotein and high density lipoprotein; lipoprotein lipase; enzymes which catalyze a series of reactions leading to the generation of hydrogen peroxide or a reduced coenzyme from glycerol; and an enzyme which catalyzes a reaction leading to the conversion of hydrogen peroxide or a reduced coenzyme into another substance, and a second reagent that contains a second selective reaction promoter, which is capable of reacting lipoprotein lipase selectively with triglycerides contained in very low density lipoprotein, intermediate density lipoprotein, low density lipoprotein and high density lipoprotein and to a method for selective measurement of triglycerides contained in very low density lipoprotein and intermediate density lipoprotein or in very low density lipoprotein in a test sample which uses the above reagent.

CLMN 25

AN 11016791 IFIPAT;IFIUDB;IFICDB

TI METHOD OF SELECTIVELY MEASURING TRIGLYCERIDES

INF Okada; Masahiko, Niigata-shi, JP

Saito; Tomohiro, Sagamihara-shi, JP

Yoshimura; Hajime, Sagamihara-shi, JP

IN Okada Masahiko (JP); Saito Tomohiro (JP); Yoshimura Hajime (JP)

PAF Masahiko OKADA, Niigata, JP

SHINO-TEST CORPORATION, Tokyo, JP

PA Shino-Test Laboratory Co Ltd JP

Unassigned Or Assigned To Individual
(13721, 68000)

AG OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314, US

PI US 2005255536 A1 20051117

AI US 2003-516291 20030604

WO 2003-JP7066 20030604

20041208 PCT 371 date

20041208 PCT 102(e) date

PRAI JP 2002-168738 20020610

FI US 2005255536 20051117

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION

ED Entered STN: 18 Nov 2005

Last Updated on STN: 18 Nov 2005

CLMN 25

L2 ANSWER 14 OF 42 USPATFULL on STN DUPLICATE 3

AB This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:87873 USPATFULL

TI Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

IN Lowe, Derek B., Hamden, CT, UNITED STATES

Wickens, Philip L., Wallingford, CT, UNITED STATES

Ma, Xin, Bethany, CT, UNITED STATES

Zhang, Mingbao, Stamford, CT, UNITED STATES
Bullock, William H., Easton, CT, UNITED STATES
Coish, Philip D.G., New Haven, CT, UNITED STATES
Mugge, Ingo A., New Haven, CT, UNITED STATES
Stolle, Andreas, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wang, Ming, Milford, CT, UNITED STATES
Wang, Yamin, Sandy Hook, CT, UNITED STATES
Zhang, Chengzhi, Orange, CT, UNITED STATES
Zhang, Hai-Jun, Middletown, CT, UNITED STATES
Zhu, Lei, Milford, CT, UNITED STATES
Tsutsumi, Manami, Stratford, CT, UNITED STATES
Livingston, James N., Guilford, CT, UNITED STATES

PA Bayer Pharmaceuticals Corporation, West Haven, CT (U.S. corporation)
PI US 2005075338 A1 20050407
US 7112597 B2 20060926
AI US 2004-949119 A1 20040922 (10)
RLI Continuation of Ser. No. US 2002-205839, filed on 25 Jul 2002, GRANTED,
Pat. No. US 6828335
PRAI US 2001-308500P 20010727 (60)
US 2002-373048P 20020416 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516
CLMN Number of Claims: 140
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 42 USPATFULL on STN DUPLICATE 4
AB The present invention relates to methods for assessing enzyme activity
utilizing a phase partition system. In addition, the present invention
also relates to methods for screening and identifying compounds that may
be used, for example, for the treatment of diabetes, diabetes-related
disorders, obesity, cardiovascular disease, cancer, and other diseases
or disorders, using this phase partition system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:75234 USPATFULL
TI Methods for screening and identifying compounds
IN Landro, James A., Cheshire, CT, UNITED STATES
Osterman, David G., Glastonbury, CT, UNITED STATES
Pickett, Walter, Madison, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT (U.S. corporation)
PI US 2005064531 A1 20050324
US 6994956 B2 20060207
AI US 2004-911242 A1 20040804 (10)
PRAI US 2003-492763P 20030804 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 1588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 42 USPATFULL on STN
AB This invention relates to substituted imidazole derivatives which have
been found to suppress appetite and induce weight loss. The invention
also provides methods for synthesis of the compounds, pharmaceutical
compositions comprising the compounds, and methods of using such

compositions for inducing weight loss and treating obesity and obesity-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:293618 USPATFULL
TI Preparation and use of imidazole derivatives for treatment of obesity
IN Smith, Roger A., Madison, CT, UNITED STATES
O'Connor, Stephen J., Guilford, CT, UNITED STATES
Wirtz, Stephan-Nicholas, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wong, Wai C., Hamden, CT, UNITED STATES
Choi, Soongyu, Trumbull, CT, UNITED STATES
Kluender, Harold C.E., Trumbull, CT, UNITED STATES
Su, Ning, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
Achebe, Furahi, West Haven, CT, UNITED STATES
Ying, Shihong, Orange, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)
PI US 2005256167 A1 20051117
AI US 2005-133751 A1 20050520 (11)
RLI Division of Ser. No. US 2002-255049, filed on 24 Sep 2002, PENDING
PRAI US 2001-324473P 20010924 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1-118
DRWN No Drawings
LN.CNT 5645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 42 USPATFULL on STN

AB The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:280425 USPATFULL
TI Phospholipase inhibitors localized in the gastrointestinal lumen
IN Hui, David, Cincinnati, CA, UNITED STATES
Charmot, Dominique, Campbell, CA, UNITED STATES
Buysse, Jerry, Los Altos, CA, UNITED STATES
PA Ilypsa, Inc., Santa Clara, CA, UNITED STATES (U.S. corporation)
PI US 2005244367 A1 20051103
AI US 2004-838879 A1 20040503 (10)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 18 OF 42 USPATFULL on STN

AB The present invention relates to heteroarylaminopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:221557 USPATFULL
TI Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IN Rudolph, Joachim, Guilford, CT, UNITED STATES
Wickens, Philip, Wallingford, CT, UNITED STATES
Chuang, Chih-Yuan, San Mateo, CA, UNITED STATES
Chen, Libing, Milford, CT, UNITED STATES
Magnuson, Steven, Wallingford, CT, UNITED STATES
Olague, Alan, Shelton, CT, UNITED STATES
Qi, Ning, Hamden, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES (U.S. corporation)
PI US 2005192294 A1 20050901
AI US 2005-64700 A1 20050224 (11)
PRAI US 2004-548331P 20040227 (60)
US 2004-572906P. 20040520 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2702

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 19 OF 42 USPATFULL on STN
AB The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:158213 USPATFULL
TI Methods and reagents for modulating cholesterol levels
IN Hayden, Michael R., Vancouver, CANADA
Brooks-Wilson, Angela R., Richmond, CANADA
Pimstone, Simon N., Vancouver, CANADA
PI US 2005136421 A1 20050623
AI US 2004-818279 A1 20040405 (10)
RLI Continuation of Ser. No. US 2003-745377, filed on 23 Dec 2003, PENDING
DT Utility
FS APPLICATION
LREP CARELLA, BYRNE, BAIN, GILFILLAN,, CECCHI, STEWART & OLSTEIN, 6 Becker Farm Road, Roseland, NJ, 07068, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 76 Drawing Page(s)
LN.CNT 5604

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 42 USPATFULL on STN
AB This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases and to pharmaceutical compositions containing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:125002 USPATFULL
TI Indane acetic acid derivatives and their use as pharmaceutical agents
IN Wickens, Philip, Wallingford, CT, UNITED STATES
Cantin, Louis-David, Hamden, CT, UNITED STATES
Kumarasinghe, Ellalahewage, Hamden, CT, UNITED STATES

Chuang, Chih-Yuan, New Haven, CT, UNITED STATES
Liang, Sidney X., Bethany, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT, UNITED STATES, 06516
(U.S. corporation)
PI US 2005107392 A1 20050519
AI US 2003-506270 A1 20030416 (10)
WO 2003-US11725 20030416
PRAI US 2002-373048P 20020416 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 21 OF 42 USPATFULL on STN
AB Drugs and foods for preventing and/or treating liver diseases,
hyperlipemia and/or diabetes containing a peptide which is composed of
L-amino acids constituting natural proteins, has an L-glutamine content
of from 15 to 60% by mass and has an average molecular weight of from
200 to 100,000; and foods containing this peptide. By taking the above
drugs or foods, effects of preventing or treating liver diseases,
hyperlipemia and/or diabetes can be exhibited. These drugs and foods are
highly efficacious and can be easily taken without any fear of side
effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:93318 USPATFULL
TI Remedies for liver diseases, hyperlipemia and diabetes
IN Horiguchi, Noboru, Sakaide, JAPAN
Horiguchi, Hiroshi, Sakaide, JAPAN
Suzuki, Yoshio, Chiyoda-ku, JAPAN
PI US 2005079996 A1 20050414
AI US 2003-506211 A1 20030228 (10)
WO 2003-JP2366 20030228
PRAI JP 2002-55812 20020301
JP 2002-278880 20020925
JP 2002-278881 20020925
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,
WASHINGTON, DC, 20006-1021, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 22 OF 42 USPATFULL on STN
AB This invention relates to novel heterocyclic compounds, compositions,
and methods for treating or preventing obesity and obesity-related
diseases. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:17403 USPATFULL
TI Phenyl substituted 5-membered nitrogen containing heterocycles for the
treatment of obesity
IN Zhang, Chenzhi, Mulberry Lane, CA, UNITED STATES
Coish, Philip D.G., New Haven, CT, UNITED STATES
O'Connor, Stephen J., Guilford, CT, UNITED STATES
Wickens, Philip, Wallingford, CT, UNITED STATES

Zhang, Hai-Jun, Middletown, CT, UNITED STATES
PI US 2005014805 A1 20050120
AI US 2004-490826 A1 20040326 (10)
WO 2002-US32895 20021015
PRAI US 2001-329236P 20011012 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516
CLMN Number of Claims: 80
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 23 OF 42 USPATFULL on STN DUPLICATE 5
AB This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:286802 USPATFULL
TI Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
IN Smith, Roger A, Madison, CT, UNITED STATES
O'Connor, Stephen J., Guilford, CT, UNITED STATES
Wong, Wai C., Hamden, CT, UNITED STATES
Choi, Soongyu, Trumbull, CT, UNITED STATES
Kluender, Harold C.E., Trumbull, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
Zhang, Zhonghua, Derby, CT, UNITED STATES
Lavoie, Rico C., Hamden, CT, UNITED STATES
Podlogar, Brent L., Hamden, CT, UNITED STATES
PI US 2004224970 A1 20041111
US 7071207 B2 20060704
AI US 2004-487976 A1 20040227 (10)
WO 2002-US30541 20020924
PRAI US 2001-60324443 20010924
DT Utility
FS APPLICATION
LREP Jeffrey M Greenman, Vice President Patents & Licensing, Bayer Corporation, 400 Morgan Lane, West Haven, CT, 06516
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 24 OF 42 USPATFULL on STN DUPLICATE 6
AB Mono-fluorinated and di-fluorinated benzothiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:88896 USPATFULL
TI Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
IN Tremont, Samuel J., St. Louis, MO, UNITED STATES

Koeller, Kevin J., Maryland Heights, MO, UNITED STATES
PA G.D. SEARLE, LLC, St. Louis, MO, UNITED STATES (U.S. corporation)
PI US 2004067872 A1 20040408
US 6740663 B2 20040525
AI US 2002-286987 A1 20021104 (10)
PRAI US 2001-330892P 20011102 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 150
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13074
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 25 OF 42 USPATFULL on STN DUPLICATE 7
AB This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:83235 USPATFULL
TI Preparation and use of imidazole derivatives for treatment of obesity
IN Smith, Roger A., Madison, CT, UNITED STATES
O'Connor, Stephen J., Guilford, CT, UNITED STATES
Wirtz, Stephan-Nicholas, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wong, Wai C., Hamden, CT, UNITED STATES
Choi, Soongyu, Trumbull, CT, UNITED STATES
Kluender, Harold C.E., Trumbull, CT, UNITED STATES
Su, Ning, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
Achebe, Furahi, West Haven, CT, UNITED STATES
Ying, Shihong, Orange, CT, UNITED STATES
PI US 2004063691 A1 20040401
US 6960601 B2 20051101
AI US 2002-255049 A1 20020924 (10)
PRAI US 2001-324473P 20010924 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, VICE PRESIDENT, PATENTS AND LICENSING, BAYER CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> DISPLAY L2
ENTER ANSWER NUMBER OR RANGE (1):26-42
ENTER DISPLAY FORMAT (FILEDEFAULT):abs bib

L2 ANSWER 26 OF 42 USPATFULL on STN
AB This invention relates to pyrrole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:335932 USPATFULL
TI Preparation and use of pyrrole derivatives for treating obesity
IN Smith, Roger A, Madison, CT, UNITED STATES
Kluender, Harold C., Trumbull, CT, UNITED STATES
Su, Ning, Hamden, CT, UNITED STATES
Lavoie, Rico C., Hamden, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
PI US 2004267028 A1 20041230
AI US 2004-489031 A1 20040305 (10)
WO 2002-US30543 20020924
PRAI US 2001-324441P 20010924 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 27 OF 42 USPATFULL on STN
AB The invention features ABC1 nucleic acids and polypeptides for the
diagnosis and treatment of abnormal cholesterol regulation. The
invention also features methods for identifying compounds for modulating
cholesterol levels in an animal (e.g., a human).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:239702 USPATFULL
TI Methods and reagents for modulating cholesterol levels
IN Hayden, Michael R., Vancouver, CANADA
Brooks-Wilson, Angela R., Richmond, CANADA
Pimstone, Simon N., Vancouver, CANADA
PI US 2004185508 A1 20040923
AI US 2004-833679 A1 20040428 (10)
RLI Continuation of Ser. No. US 2003-617334, filed on 10 Jul 2003, PENDING
Continuation of Ser. No. US 2003-452510, filed on 2 Jun 2003, PENDING
Division of Ser. No. US 2000-526193, filed on 15 Mar 2000, GRANTED, Pat.
No. US 6617122 Continuation of Ser. No. US 2000-526193, filed on 15 Mar
2000, GRANTED, Pat. No. US 6617122
PRAI US 1999-124702P 19990315 (60)
US 1999-138048P 19990608 (60)
US 1999-139600P 19990617 (60)
US 1999-151977P 19990901 (60)
DT Utility
FS APPLICATION
LREP CARELLA, BYRNE, BAIN, GILFILLAN,, CECCHI, STEWART & OLSTEIN, 6 Becker
Farm Road, Roseland, NJ, 07068
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 76 Drawing Page(s)
LN.CNT 5770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 42 USPATFULL on STN
AB Mono-fluorinated and di-fluorinated benzothiepine apical sodium
co-dependent bile acid transport (ASBT) inhibitors are disclosed
together with methods of making the same, methods of using the same to
treat hyperlipidemic conditions as well as pharmaceutical compositions
containing the same compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:228052 USPATFULL
TI Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of

apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake

IN Tremont, Samuel J., St. Louis, MO, UNITED STATES
Koeller, Kevin J., Maryland Heights, MO, UNITED STATES
PA G.D. SEARLE, LLC, St. Louis, MO (U.S. corporation)
PI US 2004176438 A1 20040909
AI US 2003-743404 A1 20031223 (10)
RLI Division of Ser. No. US 2002-286987, filed on 4 Nov 2002, GRANTED, Pat. No. US 6740663
PRAI US 2001-330892P 20011102 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 150
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 29 OF 42 USPATFULL on STN

AB The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:203360 USPATFULL
TI Methods and reagents for modulating cholesterol levels
IN Hayden, Michael R., Vancouver, CANADA
Brooks-Wiison, Angela R., Richmond, CANADA
Pimstone, Simon N., Vancouver, CANADA
PI US 2004157250 A1 20040812
AI US 2003-744465 A1 20031223 (10)
RLI Continuation of Ser. No. US 2003-617334, filed on 10 Jul 2003, PENDING
Division of Ser. No. US 2000-526193, filed on 15 Mar 2000, GRANTED, Pat. No. US 6617122
PRAI US 1999-124702P 19990315 (60)
US 1999-138048P 19990608 (60)
US 1999-139600P 19990617 (60)
US 1999-151977P 19990901 (60)
DT Utility
FS APPLICATION
LREP CARELLA, BYRNE, BAIN, GILFILLAN,, CECCHI, STEWART & OLSTEIN, 6 Becker Farm Road, Roseland, NJ, 07068
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 76 Drawing Page(s)
LN.CNT 5678
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 30 OF 42 USPATFULL on STN

AB A dry phase test strip (20) and method are provided for determining the concentration of LDL in whole blood or plasma. The inventive test strip (20) includes one stack (92) or panel that measures concentration of total cholesterol and another stack (94) or panel that measures concentration of the sum total of HDL, VLDL and chylomicrons ("non-LDLs"). The difference between the values just noted is equal to the concentration of LDL cholesterol. Dry phase test strips (20) of the present invention function at room temperature and all test results are produced from pseudo-endpoint reflectance measurements such that the test method need not be timed. Also disclosed is the capability for an improved lipid panel that provides concentration in a blood sample of HDL, total cholesterol and LDL cholesterol without relying upon the Friedewald equation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:165343 USPATFULL
TI Test strip and method for determining LDL cholesterol concentration from whole blood
IN Shull, Bruce, Indianapolis, IN, UNITED STATES
Zeng, Hyeon-Sook Lee, Indianapolis, IN, UNITED STATES
Anaokar, Sunil, Indianapolis, IL, UNITED STATES
Antonopoulos, Gena Lynn, Indianapolis, IN, UNITED STATES
PI US 2004126830 A1 20040701
AI US 2003-663555 A1 20030916 (10)
PRAI US 2002-411209P 20020916 (60)
DT Utility
FS APPLICATION
LREP MAGINOT, ADDISON & BOWMAN, BANK ONE CENTER/TOWER, 1111 MONUMENT CIRCLE, SUITE 3000, INDIANAPOLIS, IN, 46204
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 871
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 31 OF 42 USPATFULL on STN
AB This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VPAC2-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:77091 USPATFULL
TI Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use
IN Froland, Wayne A., Alameda, CA, UNITED STATES
Kelner, Drew N., Newbury Park, CA, UNITED STATES
Dumas, Michael L., Richmond, CA, UNITED STATES
Pan, Clark, Castro Valley, CA, UNITED STATES
Whelan, James, Madison, CT, UNITED STATES
Wang, Yu-Chang John, Burlingame, CA, UNITED STATES
Wang, Wei, Alameda, CA, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT (U.S. corporation)
PI US 2004058870 A1 20040325
AI US 2003-618126 A1 20030711 (10)
PRAI US 2002-395738P 20020712 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 4208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 32 OF 42 USPATFULL on STN
AB The invention features ABC1 nucleic acids and polypeptides for the

diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:77090 USPATFULL
TI Methods and reagents for modulating cholesterol levels
IN Hayden, Michael R., Vancouver, CANADA
Wilson, Angela R. Brooks, Richmond, CANADA
Pimstone, Simon N., Vancouver, CANADA
PI US 2004058869 A1 20040325
AI US 2003-617334 A1 20030710 (10)
RLI Division of Ser. No. US 2000-526193, filed on 15 Mar 2000, GRANTED, Pat. No. US 6617122
PRAI US 1999-124702P 19990315 (60)
US 1999-138048P 19990608 (60)
US 1999-139600P 19990617 (60)
US 1999-151977P 19990901 (60)
DT Utility
FS APPLICATION
LREP CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI,, STEWART & OLSTEIN, 6 Becker Farm Road, Roseland, NJ, 07068
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 76 Drawing Page(s)
LN.CNT 5678

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 33 OF 42 USPATFULL on STN

AB The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:7432 USPATFULL
TI Methods and reagents for modulating cholesterol levels
IN Hayden, Michael R., Vancouver, CANADA
Brooks-Wilson, Angela R., Richmond, CANADA
Pimstone, Simon N., Vancouver, CANADA
PI US 2004005666 A1 20040108
AI US 2003-452510 A1 20030602 (10)
RLI Division of Ser. No. US 2000-526193, filed on 15 Mar 2000, GRANTED, Pat. No. US 6617122
PRAI US 1999-124702P 19990315 (60)
US 1999-138048P 19990608 (60)
US 1999-139600P 19990617 (60)
US 1999-151977P 19990901 (60)
DT Utility
FS APPLICATION
LREP CARELLA, BYRNE, BAIN, GILFILLAN,, CECCHI, STEWART & OLSTEIN, 6 Becker Farm Road, Roseland, NJ, 07068
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 76 Drawing Page(s)
LN.CNT 5730

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 34 OF 42 USPATFULL on STN

AB The present invention relates to a method for preparing pseudo islets. In addition, the invention is also directed to methods of treating diabetes and diabetes-related disorders by administering compounds identified by the methods described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:7066 USPATFULL
TI Method for producing pseudo islets
IN Liang, Yin, Bridgewater, NJ, UNITED STATES
Zhu, Jian, North Haven, CT, UNITED STATES
Sweet, Laurel, Branford, CT, UNITED STATES
Livingston, James N., Guilford, CT, UNITED STATES
PA Bayer Pharmaceuticals Corporation, West Haven, CT (U.S. corporation)
PI US 2004005299 A1 20040108
AI US 2003-394902 A1 20030321 (10)
PRAI US 2002-366728P 20020322 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,
WEST HAVEN, CT, 06516
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1125

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 35 OF 42 USPATFULL on STN DUPLICATE 8
AB This invention relates to novel indane acetic acid derivatives which are
useful in the treatment of diseases such as diabetes, obesity,
hyperlipidemia, and atherosclerotic diseases. The invention also relates
to intermediates useful in preparation of indane acetic derivatives and
to methods of preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:306955 USPATFULL
TI Indane acetic acid derivatives and their use as pharmaceutical agents,
intermediates, and method of preparation
IN Lowe, Derek B., Hamden, CT, UNITED STATES
Wickens, Philip L., Wallingford, CT, UNITED STATES
Ma, Xin, Bethany, CT, UNITED STATES
Zhang, Mingbao, Stamford, CT, UNITED STATES
Bullock, William H., Easton, CT, UNITED STATES
Coish, Philip D.G., New Haven, CT, UNITED STATES
Mugge, Ingo A., New Haven, CT, UNITED STATES
Stolle, Andreas, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wang, Ming, Milford, CT, UNITED STATES
Wang, Yamin, Sandy Hook, CT, UNITED STATES
Zhang, Chengzhi, Orange, CT, UNITED STATES
Zhang, Hai-Jun, Middletown, CT, UNITED STATES
Zhu, Lei, Milford, CT, UNITED STATES
Tsutsumi, Manami, Stratford, CT, UNITED STATES
Livingston, James N., Guilford, CT, UNITED STATES
PI US 2003216391 A1 20031120
US 6828335 B2 20041207
AI US 2002-205839 A1 20020725 (10)
PRAI US 2001-308500P 20010727 (60)
US 2002-373048P 20020416 (60)
DT Utility
FS APPLICATION
LREP JEFFREY M. GREENMAN, VICE PRESIDENT, PATENTS AND LICENSING, BAYER
CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516
CLMN Number of Claims: 140
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 36 OF 42 USPATFULL on STN DUPLICATE 9
AB Thiepine apical sodium co-dependent bile acid transport (ASBT)

inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:277191 USPATFULL
TI Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
IN Koeller, Kevin J., Richmond Heights, MO, UNITED STATES
Tremont, Samuel J., St. Louis, MO, UNITED STATES
PA Pharmacia Corporation, St. Louis, MO, 63167 (U.S. corporation)
PI US 2003195218 A1 20031016
US 6852753 B2 20050208
AI US 2003-342201 A1 20030115 (10)
PRAI US 2002-348605P 20020117 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 150
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4133

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 37 OF 42 USPATFULL on STN
AB The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:240312 USPATFULL
TI Process for identifying modulators of ABC1 activity
IN Hayden, Michael R., Vancouver, CANADA
Brooks-Wilson, Angela R., Richmond, CANADA
Pimstone, Simon N., Vancouver, CANADA
PA Xenon Genetics, Inc., Burnaby, CANADA (non-U.S. corporation)
PI US 6617122 B1 20030909
AI US 2000-526193 20000315 (9)
PRAI US 1999-151977P 19990901 (60)
US 1999-139600P 19990617 (60)
US 1999-138048P 19990608 (60)
US 1999-124702P 19990315 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Steadman, David J.
LREP Olstein, Elliot M., Grant, Alan J.
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 76 Drawing Figure(s); 76 Drawing Page(s)
LN.CNT 5625

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 38 OF 42 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
AN 2004-122231 [12] WPIDS
AB WO 2003104486 A1 UPAB: 20060203
NOVELTY - Selectively measuring triglycerides in very low-density and intermediate-density lipoproteins comprising the use of reagents containing selective reaction accelerators capable of making triglycerides in lipoproteins to react selectively with lipoprotein lipase to produce hydrogen peroxide or a reduced coenzyme for measurement, is new.

DETAILED DESCRIPTION - Selectively measuring triglycerides in very low-density and intermediate-density lipoproteins comprises the use of:

(1) a first reagent containing a first selective reaction accelerator which is a polyoxyalkylene ether or ester compound capable of making triglycerides in low-density lipoproteins and high-density lipoproteins react with lipoprotein lipase, lipoprotein lipase and an enzyme catalyzing a series of reactions in generating hydrogen peroxide or a reduced coenzyme from glycerol, and an enzyme catalyzing a reaction in converting hydrogen peroxide or the reduced coenzyme into another substance; and

(2) a second reagent containing a second selective reaction accelerator capable of making triglycerides in very low-density lipoproteins, intermediate-density lipoproteins, low-density lipoproteins and high-density lipoproteins to selectively react with lipoprotein lipase to enable the performance of a series of reactions as before to produce hydrogen peroxide or a reduced coenzyme for measurement.

An INDEPENDENT CLAIM is also included for reagents containing the first and second selective reaction accelerators, lipoprotein lipase and other enzymes.

USE - The method is applicable in chemistry, life science and medicine particularly for the clinical examination and diagnosis of arteriosclerosis and in estimation of its risk factor.

ADVANTAGE - The method is selective and accurate, and is also versatile and automatable not requiring use of devices such as centrifuges.

AN 2004-122231 [12] WPIDS

DNC C2004-048950 [12]

DNN N2004-097914 [12]

TI Selectively measuring triglycerides in very low-density or/and intermediate-density lipoproteins in samples, applicable in clinical examination and diagnosis of arteriosclerosis

DC B04; D16; S03

IN OKADA M; SAITO T; YOSHIMURA H

PA (OKAD-I) OKADA M; (SHIN-N) SHINO-TEST CORP

CYC 29

PIA WO 2003104486 A1 20031218 (200412)* JA 67[0]

JP 2004511545 X 20051006 (200565) JA 41

US 20050255536 A1 20051117 (200576) EN

ADT WO 2003104486 A1 WO 2003-JP7066 20030604; JP 2004511545 X WO 2003-JP7066 20030604; US 20050255536 A1 WO 2003-JP7066 20030604; JP 2004511545 X JP 2004-511545 20030604; US 20050255536 A1 US 2004-516291 20041208

FDT JP 2004511545 X Based on WO 2003104486 A

PRAI JP 2002-168738 20020610

L2 ANSWER 39 OF 42 USPATFULL on STN

AB The invention relates to foods that contain both sucrose polyesters and vegetable proteins. The foods are effective in reducing blood plasma cholesterol levels. In particular, the invention is a fat-containing and protein-containing food composition comprising fat ingredients, protein ingredients, and non-fat and non-protein ingredients; wherein at least 1 gram per serving of the total fat consists essentially of a sucrose fatty acid ester having at least 4 fatty acid ester groups, each fatty acid having from about 8 to about 22 carbon atoms; and wherein at least 1.5 grams per serving (by protein content) of the total protein comprises vegetable protein.

The invention is also a method for lowering plasma cholesterol levels comprising administering to a human susceptible to or afflicted with hypercholesterolemia the present food compositions, wherein the compositions are administered to provide at least about 0.5% sucrose fatty acid ester in the daily diet (dry weight basis) and a daily dietary ratio of vegetable protein to animal protein of at least about 50:50. Importantly, the level of high density lipoproteins in the plasma

is maintained while the level of total cholesterol is lowered. The method is also effective in lowering plasma triglyceride levels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 88:79092 USPATFULL
TI Food compositions with superior blood cholesterol lowering properties
IN Seligson, Frances H., Fairfield, OH, United States
Hunter, John E., Cincinnati, OH, United States
St. Clair, Albert H., Blue Ash, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4789664 19881206
AI US 1987-120459 19871113 (7)
RLI Continuation-in-part of Ser. No. US 1986-944148, filed on 19 Dec 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Sutter, Gary M., Gutttag, Eric W., Witte, Richard C.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1,20
DRWN No Drawings
LN.CNT 985

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 40 OF 42 USPATFULL on STN

AB Disclosed herein is a method of quantitatively measuring an oxidative substance with avoiding influences of a coloring-interfering substance in the quantitative measurement of the oxidative substance by using a triphenyl methane type leuco coloring matter as a coloring reagent. Disclosed herein is also such an oxidative quantitative measurement in which the coloring sensitivity can be further adjusted. In order to avoid the influences of the coloring-interfering substance, there is employed at least one kind of (i) uricase, (ii) an anionic surface active agent and (iii) a metal chelate compound. As the triphenyl methane type leuco coloring matter, use may be made of a compound of the general formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same as or different from one another, represent a hydrogen atom or a lower alkyl group, and X.sub.1 and X.sub.2, which may be the same as or different from each other, represent a hydrogen atom, --SO.sub.3 M.sub.1, --COOM.sub.2, --O(CH.sub.2).sub.m SO.sub.3 M.sub.3, --O(CH.sub.2).sub.n COOM.sub.4 or --N(R.sub.5) (R.sub.6) in which M.sub.1, M.sub.2, M.sub.3 and M.sub.4 represent a hydrogen atom, an alkali metal ion or NH.sub.4.sup.+, R.sub.5 and R.sub.6 independently represent a hydrogen atom or a lower alkyl group, and m and n represent an integer of 2-4. Azide compound is further added or the compound represented by the general formula (I) is included with cyclodextrin or modified dextrine to adjust coloring sensitivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 88:67349 USPATFULL
TI Method of quantitatively measuring an oxidative substance using triphenyl methane type leuco-pigment as a coloring substance
IN Yamanishi, Kazuhiko, Tokyo, Japan
Hanada, Toshiro, Saitama, Japan
PA Wako Pure Chemical Industries Ltd., Osaka, Japan (non-U.S. corporation)
PI US 4778753 19881018
AI US 1984-649479 19840911 (6)
DCD 20040616
PRAI JP 1984-49950 19840315
JP 1984-65629 19840402
JP 1984-71548 19840410
DT Utility

FS Granted
EXNAM Primary Examiner: Warden, Robert J.; Assistant Examiner: Wieder, Stephen C.
LREP Cushman, Darby & Cushman
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 1410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 41 OF 42 USPATFULL on STN

AB The present invention provides a reagent for the precipitation of apo-B-containing lipoproteins, wherein it comprises 0.2 to 3 grams per liter of phosphotungstic acid and more than 2 mmols per liter of magnesium ions in aqueous solution.

The present invention also provides a process for the preparation of this reagent and a process for the precipitation of apo-B-containing lipoproteins using this reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 85:33058 USPATFULL
TI Reagent for the precipitation of apo-B-containing lipoproteins
IN Draeger, Brigitte, Tutzing, Germany, Federal Republic of
Ziegenhorn, Joachim, Starnberg, Germany, Federal Republic of
PA Boehringer Mannheim GmbH, Mannheim, Germany, Federal Republic of (non-U.S. corporation)
PI US 4521519 19850604
AI US 1982-369382 19820419 (6)
PRAI DE 1981-3117455 19810502
DT Utility
FS Granted
EXNAM Primary Examiner: Padgett, Ben R.; Assistant Examiner: Morkowitz, M.
LREP Felfe & Lynch
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 540
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 42 OF 42 USPATFULL on STN

AB A method is described for the assay of glycerol (as either free glycerol or a fatty acid ester of glycerol) in aqueous liquids such as blood serum. The method comprises the steps of

I: contacting in the presence of an electron acceptor (a) a sample to be assayed and (b) a novel reagent composition comprising

1. optionally, a lipase which hydrolyzes triglycerides to glycerol;
2. glycerol kinase;
3. adenosine triphosphate;

4. α -glycerophosphate oxidase to produce a detectable change in the presence of triglyceride or a general positive sample; and

II: detecting the occurrence of said detectable change.

The lipase is included when fatty acid esters of glycerol (i.e., triglycerides) are to be detected. Free glycerol from whatever source can be detected with a composition comprising 2-4 above. According to a preferred embodiment, the electron acceptor is oxygen and the reagent composition also includes a hydrogen peroxide indicator composition,

i.e., reagents which interact with hydrogen peroxide to produce a detectable product. The method can be used for assay of ATP. The method and reagent composition for performing the disclosed assays can be incorporated into a matrix of absorbent material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 80:64576 USPATFULL
TI Process and composition for the quantification of glycerol ATP and triglycerides
IN Esders, Theodore W., Webster, NY, United States
Goodhue, Charles T., Rochester, NY, United States
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
PI US 4241178 19801223
AI US 1978-867641 19780106 (5)
RLI Continuation-in-part of Ser. No. US 1976-715797, filed on 19 Aug 1976, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kepplinger, Esther M.
LREP Dahl, Torger N.
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.